2022-502891-22-00招募中1 期
A study of HFB200603 as a single agent and in combination with Tislelizumab in patients with advanced solid tumors
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Hifibio Inc.
- 入组人数
- 96
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Regulatory Submissions
Scientific
Hifibio Inc.
研究点 (7)
Loading locations...
相似试验
已完成
1 期
A research study looking at how the compound NNC0194-0499 works with birth control pills in women not able to bear children.2023-503595-24-00Novo Nordisk A/S30
已完成
1 期
[HIBOU] : A phase I, single-center, randomized, double-blind, single-dose escalation, placebo-controlled clinical study to evaluate the safety, tolerability and pharmacokinetics of IMP21052 administered intravenously in three groups of healthy male and female volunteers2023-509035-30-00Direction Centrale Du Service De Sante Des Armees40
招募中
1 期
A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer2023-510307-22-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.116
招募中
1 期
A study to see the effect of NNC0194-0499 alone or in combination with semaglutide on blood sugar control in people living with type 1 diabetes.2024-519533-38-00Novo Nordisk A/S96
进行中（未招募）
2 期
评价 HZ-H08905 的有效性和安全性的研究CTR2025444191